Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions

Yoshiyuki Shirasaka, Jennifer E. Sager, Justin D. Lutz, Connie Davis and Nina Isoherranen
Drug Metabolism and Disposition July 2013, 41 (7) 1414-1424; DOI: https://doi.org/10.1124/dmd.113.051722
Yoshiyuki Shirasaka
Department of Pharmaceutics, School of Pharmacy (Y.S., J.E.S., J.D.L., N.I.), and Division of Nephrology, Department of Medicine, School of Medicine (C.D.) University of Washington, Seattle, Washington; and Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan (Y.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer E. Sager
Department of Pharmaceutics, School of Pharmacy (Y.S., J.E.S., J.D.L., N.I.), and Division of Nephrology, Department of Medicine, School of Medicine (C.D.) University of Washington, Seattle, Washington; and Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan (Y.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justin D. Lutz
Department of Pharmaceutics, School of Pharmacy (Y.S., J.E.S., J.D.L., N.I.), and Division of Nephrology, Department of Medicine, School of Medicine (C.D.) University of Washington, Seattle, Washington; and Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan (Y.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Connie Davis
Department of Pharmaceutics, School of Pharmacy (Y.S., J.E.S., J.D.L., N.I.), and Division of Nephrology, Department of Medicine, School of Medicine (C.D.) University of Washington, Seattle, Washington; and Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan (Y.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nina Isoherranen
Department of Pharmaceutics, School of Pharmacy (Y.S., J.E.S., J.D.L., N.I.), and Division of Nephrology, Department of Medicine, School of Medicine (C.D.) University of Washington, Seattle, Washington; and Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan (Y.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

vol. 41 no. 7 1414-1424
DOI 
https://doi.org/10.1124/dmd.113.051722
PubMed 
23620487

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received February 23, 2013
  • Accepted April 25, 2013
  • Published online June 13, 2013.

Article Versions

  • Earlier version (April 25, 2013 - 10:45).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Yoshiyuki Shirasaka,
  2. Jennifer E. Sager,
  3. Justin D. Lutz,
  4. Connie Davis, and
  5. Nina Isoherranen
  1. Department of Pharmaceutics, School of Pharmacy (Y.S., J.E.S., J.D.L., N.I.), and Division of Nephrology, Department of Medicine, School of Medicine (C.D.) University of Washington, Seattle, Washington; and Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan (Y.S.)
  1. Address correspondence to:
    Dr. Nina Isoherranen, Department of Pharmaceutics, School of Pharmacy, University of Washington, H272 Health Sciences Building, Box 357610, University of Washington, Seattle, WA 98195-7610. E-mail: ni2{at}u.washington.edu
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: April 2013 to January 2021

AbstractFullPdf
Apr 2013242062
May 20133710145
Jun 201371042147
Jul 201349139100
Aug 20132341948
Sep 20132181548
Oct 20131243155
Nov 20131022456
Dec 201381824
Jan 2014671322
Feb 2014481729
Mar 20141053445
Apr 2014672542
May 2014501619
Jun 201466921
Jul 2014592429
Aug 2014452226
Sep 2014691830
Oct 2014612430
Nov 2014643741
Dec 2014441923
Jan 2015282834
Feb 2015542335
Mar 2015472149
Apr 2015451534
May 2015241823
Jun 2015402327
Jul 2015191821
Aug 2015412219
Sep 2015451718
Oct 2015322431
Nov 2015352123
Dec 2015321927
Jan 2016451642
Feb 2016361924
Mar 2016371325
Apr 2016422036
May 2016241745
Jun 2016211012
Jul 2016251216
Aug 2016271212
Sep 2016221119
Oct 201693316
Nov 2016146841
Dec 2016136128
Jan 201783115
Feb 201742417
Mar 201792728
Apr 2017104029
May 2017123426
Jun 2017112721
Jul 2017132017
Aug 2017153148
Sep 2017194936
Oct 2017125149
Nov 2017264056
Dec 2017164727
Jan 20181834823
Feb 20182317823
Mar 20182525831
Apr 20181115722
May 20181512931
Jun 2018199239
Jul 201894435
Aug 2018205125
Sep 201882916
Oct 2018159233
Nov 2018198326
Dec 2018771710
Jan 20191021018
Feb 201976713
Mar 201966412
Apr 201969835
May 2019521024
Jun 201946917
Jul 201944514
Aug 201968911
Sep 201965329
Oct 201988722
Nov 201968415
Dec 2019511113
Jan 2020631710
Feb 20203359
Mar 20206138
Apr 20207138
May 2020124820
Jun 20204756
Jul 202065129
Aug 20202848
Sep 20207179
Oct 202011789
Nov 202082910
Dec 20201451029
Jan 202149105

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 41 (7)
Drug Metabolism and Disposition
Vol. 41, Issue 7
1 Jul 2013
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

CYP2C19 and CYP3A4 Inhibition by Omeprazole Metabolites

Yoshiyuki Shirasaka, Jennifer E. Sager, Justin D. Lutz, Connie Davis and Nina Isoherranen
Drug Metabolism and Disposition July 1, 2013, 41 (7) 1414-1424; DOI: https://doi.org/10.1124/dmd.113.051722

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

CYP2C19 and CYP3A4 Inhibition by Omeprazole Metabolites

Yoshiyuki Shirasaka, Jennifer E. Sager, Justin D. Lutz, Connie Davis and Nina Isoherranen
Drug Metabolism and Disposition July 1, 2013, 41 (7) 1414-1424; DOI: https://doi.org/10.1124/dmd.113.051722
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • BSEP Function in Suspension Hepatocytes
  • Candesartan glucuronide serves as a CYP2C8 inhibitor
  • Role of AADAC on eslicarbazepine acetate hydrolysis
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics